{
  "model": "gemini-3-pro-preview",
  "agentReasoning": "medium",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 3,
  "workspacePath": "workspaces/gemini-3-pro-preview-tumor-vaccine-ici-run-3",
  "success": false,
  "schemaPass": false,
  "toolTracePass": true,
  "graderPass": false,
  "durationMs": 228305,
  "agentCostUsd": 0.184704,
  "graderCostUsd": 0,
  "totalCostUsd": 0.184704,
  "agentUsage": {
    "promptTokens": 48540,
    "cachedTokens": 16600,
    "responseTokens": 2707,
    "thinkingTokens": 7085,
    "totalTokens": 58332
  },
  "graderUsage": {
    "promptTokens": 0,
    "cachedTokens": 0,
    "responseTokens": 0,
    "thinkingTokens": 0,
    "totalTokens": 0
  },
  "totalUsage": {
    "promptTokens": 48540,
    "cachedTokens": 16600,
    "responseTokens": 2707,
    "thinkingTokens": 7085,
    "totalTokens": 58332
  },
  "modelVersions": [
    "gemini-3-pro-preview"
  ],
  "agentFinalText": "The required JSON output files have been generated based on the report and schemas.\n\nChecklist of written output files:\n- `output/study_overview.json`\n- `output/quantitative_findings.json`\n- `output/claim_audit.json`\n- `output/public_summary.json`",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"mixed\"\n  },\n  \"core_question\": \"whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy\",\n      \"label\": \"Mouse efficacy cohort\",\n      \"sample_size_or_observations\": \"78 mice\",\n      \"description\": \"Tumor-bearing mice pooled across repeat experiments receiving combination therapy.\"\n    },\n    {\n      \"id\": \"mouse-control\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84 mice\",\n      \"description\": \"Tumor-bearing mice pooled across matched controls (vaccine only, ICI only, and vehicle).\"\n    },\n    {\n      \"id\": \"human-retrospective\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\"\n  ]\n}"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination broadens antigen presentation.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        { \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3%\", \"line_ref\": \"L28\" },\n        { \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6%\", \"line_ref\": \"L29\" }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"Prior SARS-CoV-2 mRNA vaccination is associated with better ICI outcomes in humans.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        { \"quote\": \"Retrospective human survival comparison p-value | p=0.01\", \"line_ref\": \"L30\" },\n        { \"quote\": \"Vaccinated subgroup had improved survival under ICI treatment\", \"line_ref\": \"L30\" }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Type I interferon signaling is required for the sensitization effect.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        { \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\", \"line_ref\": \"L39\" },\n        { \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0\", \"line_ref\": \"L31\" }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Combination therapy increases immune infiltration.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        { \"quote\": \"Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x\", \"line_ref\": \"L33\" },\n        { \"quote\": \"Increased immune infiltration with combination therapy\", \"line_ref\": \"L33\" }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": false,
      "groundingValid": false,
      "errors": [
        "plain_language_summary: Too big: expected string to have <=1200 characters"
      ],
      "content": "{\n  \"headline\": \"mRNA Vaccines May Boost Cancer Immunotherapy Effectiveness by Alerting the Immune System\",\n  \"plain_language_summary\": \"Immune checkpoint inhibitors are drugs that help the immune system fight cancer, but they do not work for everyone. This study explored whether giving an mRNA vaccine directly into a tumor could make these drugs work better. The researchers tested this in mice and looked at past data from human patients. In mice, they found that injecting an mRNA vaccine into the tumor triggered a strong 'alarm' signal called type I interferon. This signal caused the tumor cells to show more of their proteins on their surface, making them easier for the immune system to spot and attack. When the vaccine was combined with immune checkpoint inhibitors, the treatment controlled tumors better than either treatment alone. The researchers also looked at a group of patients with metastatic cancer who had received immune checkpoint inhibitors. They found that those who had previously received a SARS-CoV-2 mRNA vaccine lived longer than those who had not, suggesting a possible link. However, this human part of the study was looking back at old data and wasn't a controlled experiment, so other factors could be involved. Overall, the findings suggest that mRNA vaccines might help 'prime' tumors to respond to immunotherapy, but more research is needed to confirm this in people.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination triggers type I interferon signaling that increases antigen presentation.\",\n    \"Combining mRNA vaccination with anti-PD-L1 therapy improves tumor control in mouse models.\",\n    \"Retrospective analysis suggests prior SARS-CoV-2 mRNA vaccination might correlate with better ICI outcomes.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human data is retrospective and non-randomized, meaning other factors could explain the results.\",\n    \"Mouse models of cancer do not perfectly mimic the complexity of human tumors.\",\n    \"Vaccination timing and tumor types varied widely among the patients studied.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune Checkpoint Inhibitor\",\n      \"definition\": \"A drug that blocks proteins that stop the immune system from attacking cancer cells, effectively releasing the 'brakes' on the immune response.\"\n    },\n    {\n      \"term\": \"Intratumoral\",\n      \"definition\": \"Administration of a substance, such as a drug or vaccine, directly into a tumor to target the cancer site specifically.\"\n    },\n    {\n      \"term\": \"Type I Interferon\",\n      \"definition\": \"A group of proteins that cells release in response to viruses, acting as a warning signal to the immune system to fight infection or abnormal cells.\"\n    },\n    {\n      \"term\": \"Retrospective Study\",\n      \"definition\": \"A study that looks back at data that has already been collected, rather than setting up an experiment to collect new data moving forward.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Does the timing of the mRNA vaccine relative to the immunotherapy treatment matter for the effect?\",\n    \"Will these findings hold true in a prospective, randomized clinical trial with human patients?\",\n    \"Can this approach be effective across different types of cancers that are currently resistant to immunotherapy?\"\n  ]\n}"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 22,
    "failedCalls": 0,
    "toolsUsed": [
      "list_directory",
      "read_file",
      "write_file"
    ],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 5,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 6,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 7,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 8,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 9,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 10,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 11,
        "toolName": "write_file"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-13T17:46:32.168Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "schemas",
        "timestamp": "2026-02-13T17:46:49.874Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-13T17:47:10.425Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-13T17:47:40.813Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-13T17:47:49.824Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-13T17:48:00.237Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-13T17:48:16.781Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-13T17:49:19.310Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-13T17:49:28.712Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-13T17:49:44.336Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-13T17:49:53.523Z"
      }
    ]
  },
  "grader": {
    "model": "chatgpt-gpt-5.2",
    "error": "LLM JSON call failed after 2 attempt(s)"
  }
}
